The value I, and many others, see in $ABCL lies far beyond the value of ABCL635 alone:
“A critic could look at our ABCL635 Phase 2 asset and our two undisclosed preclinical assets (ABCL386 and ABCL688) and make the claim that for $1B of invested capital, they would have
